Immunohistochemical prognostic markers in bladder cancer

Journal of B.U.ON.

Volumn 7, Issue 3, 2002, Pages 207-216

  Ioachim, Elli ^a   Stavropoulos, N E ^a   Charalabopoulos, K ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Bladder cancer; Immunohistochemistry; Prognostic markers

Indexed keywords

BIOLOGICAL MARKER; CASPASE; CATHEPSIN D; CELL ADHESION MOLECULE; CYCLIN D1; CYCLIN E; CYCLINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; HLA DR ANTIGEN; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; METALLOTHIONEIN; MYC PROTEIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEINASE; RETINOBLASTOMA PROTEIN; THROMBOSPONDIN 1; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

APOPTOSIS; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; ECOSYSTEM; EXTRACELLULAR MATRIX; FOLLOW UP; GENE MUTATION; GENETIC PREDISPOSITION; GROWTH REGULATION; HOST CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; ONCOGENE; ONCOGENE C JUN; ONCOGENE C MYC; ONCOGENE NEU; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0036662265     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Heney N, Proppe K, Prout GJ. Invasive bladder cancer: tumour configuration, lymphatic infiltration and survival. J Urol 1983; 130: 895-897.
2. Heney N, Ahmed S, Flanagan M. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083-1086.
3. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31:13-20.
4. Okamura K, Miyake K, Koshikawa T, Asai J. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J Urol 1990; 144:875-878.
5. Fontana D, Bellina M, Gubetta L et al. Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J Urol 1992;148:1149-1151.
6. Cohen MB, Waldman FM, Carroll PR, Kerschmann R, Chew K, Mayall BH. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol 1993; 24:772-778.
7. Tsujihashi H, Nakanishi A, Matsuda H, Uejima S, Kurita T. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 1991; 145:846-849.
8. Mulder AH, Van Hootegem JC, Sylvester R et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 1992; 166:37-43.
9. Stavropoulos NE, Ioachim E, Hastazeris K, Kitsiou E, Stefanaki S, Agnantis NJ. Growth fractions in bladder cancer defined by Ki-67: Association with cancer grade, category and recurrence rate of superficial lesions. Br J Urology 1993: 72: 736-739.
10. Bush C, Price P, Norton J et al. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br J Cancer 1991; 64:357-360.
11. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996; 155:316-320.
12. Ioachim E, Charchandi A, Stavropoulos NE, Skopelitou A, Athanassiou E, Agnantis NJ. Immunohistochemical expression of Retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma. Histol Histopathol 2000; 15: 721-727.
13. Stavropoulos NE, Ioachim E, Charchanti A et al. Tumor markers in stage P1 bladder cancer. Anticancer Res 2001; 21: 1495-1498.
14. Chen G, Lin MS, Li RC. Expression and prognostic value of proliferating cell nuclear antigen in transitional cell carcinoma of the urinary bladder. Urol Res 1997; 25: 25-30.
15. Serio G. PCNA/cyclin expression in transitional cell carcinomas of the human bladder: its correlation with Ki-67 and epidermal growth factor receptor immunostaining. Pathologica 1994; 86:161-166.
16. Korkolopoulou P, Christodoulou P, Kapralos P et al. The role of p53, MDM2 and c-erbB-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract 1997; 193: 767-775.
17. Vorreuther R, Hake R, Borchmann P, Lukowsky S, Thiele J, Engelmann U. Expression of immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors. Urol Int 1997; 59: 88-94.
18. Iizumi T, Iiyama T, Tanaka W et al. Immunohistochemical studies of proliferating cell nuclear antigen and cathepsinD in transitional cell carcinoma of the urinary bladder. Urol Int 1997; 59: 81-87.
19. Moch H, Sauter G, Moore D, Mihatsch M, Gudat F, Waldman F. p53 and erb-2 protein overexpression are associated with early invasion and metastasis inbladder cancer. Virchows Arch A Pathol Anat 1993; 423: 329-334.
20. Sato K, Moriyama M, Mori S et al. An immunohistochemical evaluation of c- erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70: 2493-2498.
21. Gorgoulis V, Barbatis C, Poulias I, Karameris A. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erbB-2 gene product in transitional cell carcinomas of the urinary bladder: A study in Greek patients. Modern Pathol 1995; 8: 758-764.
22. Imai T, Kimura M, Takeda M, Tomita Y. Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder. Br J Cancer 1995; 71: 69-72.
23. Berner A, Jacobsen AB, Fossa SD, Nesland JM. Expression of c-erbB-2 protein, neuron-specific enolase and DNA flow cytometry in locally advanced transitional cell carcinoma of the urinary bladder. Histopathology 1993; 22: 327-333.
24. Koyuncuoglu M, Kargi A, Cingoz S, Kirkali Z. Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters. Cancer Lett 1998; 126: 143-148.
25. Masters JR, Vesey SG, Munn CF, Evan GI, Watson JV. c-myc oncoprotein levels in bladder cancer. Urol Res 1988; 16:341-344.
26. Lipponen PK. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995; 175:203-210.
27. Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM. Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature 1988; 334:629-631.
28. Sasson-Corsi P, Lamph WW, Kamps M, Verma IM. fos-associated cellular p39 is related to nuclear transcription factor AP-1. Cell 1988;54:553-560.
29. Tiniakos DG, Mellon K, Anderson JJ, Robinson MC, Neal DE, Horne CH. c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. Br J Urol 1994; 74:757-761.
30. Skopelitou A, Hadjiyannakis M, Dimopoulos D et al. p53 and c-jun expression in urinary bladder transitional cell carcinoma: Correlation with proliferating cell nuclear antigen (PCNA), histological grade and clinical stage. Eur Urol 1997; 31: 464-471.
31. Lianes P, Orlow I, Zhang ZF et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86: 1325-1330.
32. Schmitz-Drager BJ, Kushima M, Goebell P et al. p53 and Mdm2 in the development and progression of bladder cancer. Eur Urol 1997; 32: 487-493.
33. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-1264.
34. Kuczyk MA, Bokemeyer C, Serth J et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A: 2243-2247.
35. Serth J, Kuczyk MA, Bokemeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71: 201-205.
36. Underwood MA, Reeves J, Smith G et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 1996; 77: 659-666.
37. Cordon-Cardo C, Zhang ZF, Dalbagni G et al. Cooperative effects of p53 and pRb alterations in primary superficial bladder tumours. Cancer Res 1997; 57: 1217-1221.
38. Raitanen MP, Tammela TL, Kallioinen M, Isola J. p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 1997; 157: 1250-1253.
39. Atug F, Turkeri L, Ozyurek M, Akdas A. Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder. Int. Urol. Nephrol 1998; 30:455-461.
40. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Giakopoulou H, Dimopoulos MA. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998; 29: 146-154.
41. Liukkonen TJ, Lippon PK, Helle M, Jauhiainen KE. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group. Urol Res 1997; 25: 1-7.
42. Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Anticancer Res 1998; 18: 4717-4722.
43. Wu T.T, Chen JH, Lee YH, Huang J.K. The role of bcl-2, p53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758-760.
44. Lee E, Park I, Lee C. Prognostic markers of intravesical bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers. Int J Urol 1997, 4: 552-556.
45. Wright C, Thomas D, Mellon K, Neal D, Horne C. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki-67 index. Br J Urol 1995; 75: 173-179.
46. Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Prevalence and clinical significance of HER/2neu, p53, and Rb expression in primary superficial bladder cancer. J Urol 1996; 155: 1784-1788.
47. Fuse H, Mizune I, Sakamoto M, Katayama T. Epidermal growth factor in urine from the patients with urothelial tumors. Urol Int 1992; 48:261-264.
48. Messing EM, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology 1994; 44:502-506.
49. Ravery V, Grignon D, Angulo J et al. Evaluation of epidermal growth factor receptor, transforming growth factor, epidermal growth factor and c-erb B2 in the progression of invasive bladder cancer. Urol Res 1997; 25: 9-17.
50. Coombs LM, Pigott DA, Eydmann ME, Proctor AJ, Knowles MA. Reduced expression of TGF β is associated with advanced disease in transitional cell carcinoma. Br J Cancer 1993; 67: 578-584.
51. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55: 510-513.
52. Arima J, Imazono Y, Takebayashi Y et al. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 2000; 88: 1131-1138.
53. Lee CC, Yamamoto S, Morimura K et al. Significance of cyclin D over-expression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997; 15: 780-789.
54. Osman I, Scher H, Zhang ZF et al. Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer. Clin Cancer Res 1997; 3: 2247-2251.
55. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997; 75: 1788-1792.
56. Suwa Y, Takano Y, Iki M et al. Cyclin D1 protein overexpression is related to tumor differentiation, but not to tumor progression or proliferative activity, in transitional cell carcinoma of the bladder. J Urol 1998; 160: 897-900.
57. Wagner U, Suess K, Luginbuhl T et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999; 188: 44-50.
58. Kip1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999; 155: 1129-1136.
59. Makiyama K, Masuda M, Takano Y et al. Cyclin E overexpression in transitional cell carcinoma of the bladder. Cancer Lett 2000; 14: 193-198.
60. Richter J, Wagner U, Kononen J. High-throughout tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000; 157: 787-794.
61. Clasen S, Schulz WA, Gerharz CD. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 1998; 77: 515-521.
62. Korkolopoulou P, Konstantinidou AE, Thomas-Tsagli E et al. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Appl Immunohistochem Molec Morphol 2000; 8: 285-292.
63. Lipponen P, Aaltomaa S, Eskolinon M, Ala-Opas M, Kosma VM. Expression of p21 (waf1/cip1) protein in transitional cell bladder tumours and its prognostic value. Eur Urol 1998; 34; 237-243.
64. Osen I, Fossa SD, Majak B, Rotterud R, Berner A. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br J Urol 1998; 81: 862-869.
65. Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI. Decreasing of p27(Kip1) and cycline E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001; 84: 1242-1251.
66. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27 Kip 1. Hum Pathol 2000; 31: 751-760.
67. Burton PBJ, Anderson ChJ, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. New Engl J Med 2000; 343: 1418-1420.
68. Chyle V, Pollack A, Czerniak B et al. Apoptosis and down-staging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol 1996; 35: 281-287.
69. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994; 73: 333-339.
70. Korsmeyer SJ. Regulators of cell death. Trends Genet 1995; 11: 101-105.
71. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996; 155: 316-320.
72. Bilin VN, Tomita Y, Kawasaki T, Takeda M, Takahashi K. Variable bcl-2 phenotype in benign and malignant lesions on urothelium. Cancer Lett 1998; 128: 87-92.
73. Kong G, Shin KY, Oh YH et al. Bcl-2 and p53 expression in invasive bladder cancers. Acta Oncol 1998; 37: 715-720.
74. Asci R, Yildiz L, Sarikaya S, Buyukalpelli R, Yilmaz A, Kandemir B. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder. Urol Int 2001; 67: 34-40.
75. Gorstein F. The dynamic extracellular matrix. Human Pathol 1988; 19: 751-752.
76. Cidadao AJ. Interactions between fibronectin, glycosaminoglycans and native collagen fibrils: an EM study in artificial three-dimensional extracellular matrices. Eur J Cell Biol 1989; 48: 303-312.
77. Ampbell JH, Terranova VP. Laminin: molecular organization and biological function: J Oral Pathol 1988; 17: 309-323.
78. Gould V, Kouloulis G, Virtanen I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Diff Dev 1990;32: 409-416.
79. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
80. Vlodavsky I, Bar-Shavit R, Korner G, Fuks Z. Extracellular matrix-bound growth factors, enzymes and plasma proteins. In: Rohrbach DH, Timpl R (eds). Basement membranes: cellular and molecular aspects. Academic Press, Orlando FL, 1993, pp 327-343.
81. Koukoulis GK, Howeedy AA, Korhonen M, Virtanen I, Gould VE. Distribution of tenascin, cellular fibronectins and integrins in the normal hyperplastic and neoplastic breast. J Submicrosc Cytol Pathol 1993; 25: 285-295.
82. Conn IG, Crocker J, Wallace DM, Hughes MA, Hilton CJ. Basement membranes in urothelial carcinoma. Br J Urol 1987; 60: 536-542.
83. Schapers R, Pauwels R, Havenith MG, Smeets AW, van den Brandt PA, Bosman FT. Prognostic significance of type IV collagen and laminin immunoreactivity in urothelial carcinomas of the bladder. Cancer 1990; 66: 2583-2588.
84. Abou Farha KM, Janknegt RA, Kester AD, Arends JW. Value of immunohisto- chemical laminin staining in transitional cell carcinoma of human bladder. Urol Int 1993; 50: 133-140.
85. Ozer E, Mungan MU, Tuna B, Kazimoglu H, Yorukoglu K, Kirkali Z. Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer. Urology 1999; 54: 50-55.
86. Tiita O, Wahlstrom T, Virtanen I, Gould VE. Tenascin in inflammatory conditions and neoplasms of the urinary bladder. Virchows Arch B 1993; 63: 283-287.
87. Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas. J Urol 1995; 154: 237-241.
88. Lipponen P. Expression of cathepsin D in transitional cell bladder tumors. J Pathol 1996; 178: 59-64.
89. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992; 50: 871-873.
90. Hasui Y, Marutsuka K, Asada Y, Osaka Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996; 47: 34-37.
91. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol 2001; 165: 1769-1772
92. Nakopoulou L, Gakiopoulou H, Zervas A et al. MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl Immunohistochem Molecul Morphol 2001; 9: 130-137.
93. Papathoma AS, Petraki C, Grigorakis A et al. Prognostic significance of matrix metalloproteinase 2 and 9 in bladder cancer. Anticancer Res 2000; 20: 2009-2013.
94. Nakopoulou I, Zervas A, Gakiopoulou-Givalou H et al. Prognostic value of E-cadherin, beta-catenin, p120ctn in patients with transitional cell bladder cancer. Anticancer Res 2000; 20: 4571-4578.
95. Byrne RR, Shariat SF, Brown R et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001; 165: 1473-1479.
96. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998; 186: 157-164.
97. Ioachim E, Charchandi A, Stavropoulos NE, Athanassiou E, Agnantis NJ. Expression of the cell adhesion molecule CD44 in transitional cell carcinoma of the urinary bladder. J Tumour Marker Oncol 1997; 12: 27-36.
98. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762-766.
99. Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 1603-1612.
100. Philp EA, Stephenson TJ, Reed MW. Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder. Br J Urol 1996; 77: 352-357.
101. Chaudhary R, Bromley M, Clarke NW et al. Prognostic relevance of microvessel density in cancer of the urinary bladder. Anticancer Res 1999; 19: 3479-348.
102. Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89: 219-227.
103. Yoshimura R, Sano H. Mitsuhashi M, Kohno M, Chargui J, Wada S. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 2001; 165: 1468-1472.
104. Ioachim-Velogianni E, Stavropoulos NE, Kitsiou E, Stefanaki S, Agnantis NJ. HLA-DR antigen expression and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. J Pathol 1994; 174: 183-189.
105. Ioachim-Velogianni E, Kitsiou E, Stavropoulos NE, Agnantis NJ, Stefanaki S. Distribution of CDIa positive Langerhans cells and lymphocytes subsets intransitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. J Pathol 1995; 177: 401-406.
106. Zuk J, Walker R. HLA class II sublocus expression in benign and malignant breast epithelium. J Pathol 1988; 155: 301-309.
107. Stavropoulos NE, Ioachim E, Pavlidis N, Pappa L, Kalomiris P, Agnantis NJ. Local immune response after intravesical interferon gamma in superficial bladder cancer. Br J Urol 1998; 81: 875-879.
108. Stavropoulos NE, Ioachim E, Pappa L, Hastazeris K, Agnantis NJ. Anti-proliferative activity of interferon gamma in superficial bladder cancer. Anticancer Res 1999; 19: 4529-4543.
109. Brown DH, Wagner TT, Bahnson RR. Interferons and bladder cancer. Urol Clin North Am 2000; 27: 171-178.
110. Rios Gonzalez E, Martinez-Pineiro Lorenzo L, Martinez-Pineiro Carames JA, de la Pena Barthel JJ. Immunotherapy in superficial bladder carcinoma. Arch Esp Urol 2000; 53: 879-892.
111. Saika T, Tsushima T. Ochi J et al. Overexpression of metallothionein and drug-resistance in bladder cancer. Int J Urol 1994; 1: 135-139.
112. Ioachim E, Charchanti A, Stavropoulos NE, Michael M, Athanassiou E, Agnantis NJ. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: An immunohistochemical study including correlation with HLA-DR antigen p53, and proliferation indices. Anticancer Res 2001; 21: 1757-1761.
113. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. New Engl J Med 1999; 341: 452-453.